Herpes News and Research

RSS
Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.
Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

New test capable of detecting all viruses that affect people and animals

New test capable of detecting all viruses that affect people and animals

New test identifies viruses that infect people and animals

New test identifies viruses that infect people and animals

Vaginal silicone ring may protect women against HIV, herpes virus

Vaginal silicone ring may protect women against HIV, herpes virus

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

New study provides biological explanation for how DMPA increases risk of HIV infection

New study provides biological explanation for how DMPA increases risk of HIV infection

Discovery could open up door for cancer research and treatment

Discovery could open up door for cancer research and treatment

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Researchers capture images of immune cell interactions rallying to destroy herpes simplex virus

Researchers capture images of immune cell interactions rallying to destroy herpes simplex virus

Reducing amyloid fibril levels in semen may help reduce transmission of HIV

Reducing amyloid fibril levels in semen may help reduce transmission of HIV

Molecular tweezer blocks HIV, breaks up proteins in semen that boost infection

Molecular tweezer blocks HIV, breaks up proteins in semen that boost infection

NanoViricides speeds up HerpeCide drug development program

NanoViricides speeds up HerpeCide drug development program

Determining the dynein-dynactin complex structure: an interview with Dr Gabriel C. Lander

Determining the dynein-dynactin complex structure: an interview with Dr Gabriel C. Lander

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.